OptimizeRx (NASDAQ:OPRX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of OptimizeRx (NASDAQ:OPRX) from a buy rating to a strong-buy rating in a research report released on Sunday morning.

A number of other equities research analysts have also recently issued reports on OPRX. JMP Securities lifted their price target on shares of OptimizeRx from $20.00 to $23.00 and gave the company a “market outperform” rating in a research note on Friday, October 10th. Citigroup reaffirmed an “outperform” rating on shares of OptimizeRx in a research note on Friday, October 10th. Stephens cut their price objective on OptimizeRx from $20.00 to $17.00 and set an “equal weight” rating for the company in a research note on Monday, November 17th. Weiss Ratings reissued a “sell (d+)” rating on shares of OptimizeRx in a report on Monday, December 8th. Finally, Citizens Jmp raised their target price on OptimizeRx from $23.00 to $24.00 and gave the company a “market outperform” rating in a research report on Friday, November 7th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $16.88.

OptimizeRx Price Performance

NASDAQ:OPRX opened at $12.77 on Friday. The company has a quick ratio of 3.05, a current ratio of 3.05 and a debt-to-equity ratio of 0.20. OptimizeRx has a 52 week low of $3.99 and a 52 week high of $22.25. The stock’s 50-day moving average price is $16.84 and its 200-day moving average price is $15.97. The stock has a market capitalization of $238.03 million, a PE ratio of 32.95 and a beta of 1.10.

OptimizeRx (NASDAQ:OPRX) last issued its quarterly earnings results on Thursday, November 6th. The company reported $0.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.03 by $0.17. OptimizeRx had a return on equity of 6.37% and a net margin of 0.03%.The company had revenue of $26.07 million for the quarter, compared to the consensus estimate of $23.83 million. As a group, equities analysts expect that OptimizeRx will post -0.33 EPS for the current fiscal year.

Insider Buying and Selling at OptimizeRx

In other news, CEO Stephen L. Silvestro sold 1,620 shares of the company’s stock in a transaction that occurred on Friday, October 3rd. The stock was sold at an average price of $18.75, for a total value of $30,375.00. Following the completion of the sale, the chief executive officer directly owned 188,916 shares in the company, valued at $3,542,175. This represents a 0.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 5.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On OptimizeRx

A number of institutional investors and hedge funds have recently added to or reduced their stakes in OPRX. American Century Companies Inc. increased its stake in shares of OptimizeRx by 9.6% in the 1st quarter. American Century Companies Inc. now owns 15,783 shares of the company’s stock worth $137,000 after acquiring an additional 1,387 shares during the last quarter. Nisa Investment Advisors LLC grew its holdings in shares of OptimizeRx by 600.0% in the second quarter. Nisa Investment Advisors LLC now owns 2,121 shares of the company’s stock valued at $29,000 after purchasing an additional 1,818 shares during the period. Parkman Healthcare Partners LLC increased its position in OptimizeRx by 0.4% during the third quarter. Parkman Healthcare Partners LLC now owns 509,611 shares of the company’s stock worth $10,447,000 after purchasing an additional 2,188 shares during the last quarter. BNP Paribas Financial Markets raised its stake in OptimizeRx by 119.2% during the second quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock worth $55,000 after purchasing an additional 2,215 shares during the period. Finally, Rhumbline Advisers boosted its holdings in OptimizeRx by 10.5% in the 1st quarter. Rhumbline Advisers now owns 27,785 shares of the company’s stock valued at $241,000 after purchasing an additional 2,636 shares during the last quarter. Institutional investors and hedge funds own 76.47% of the company’s stock.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.